Targeting key immune molecules—such as inhibiting the cGAS–STING pathway, or targeting TLR4, NLRP3, or IL‐1β signaling—has shown promise for improved safety profiles in both ALD and MASLD. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.